TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1804650
Drug: AS-4370 10
Normalized name: octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AS-4370 10 mg
Study: 25365188
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 50 mg·kg(‐1) silybin for 15 consecutive days
Study: 25365188
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 mg·kg(‐1) silybin
Study: 20372991
Drug: Azithromycin capsules
Normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin capsules (fed state)
Study: 17963629
Drug: Valsartan/HCTZ 80/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ 80/12.5 mg once daily
Study: 2017535
Drug: Dexamethasone 1.5
Normalized name: dexamethasone 1.5 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 1.5 mg
Study: 6637819
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine 0.15 mg/kg
Study: 6637819
Drug: Furosemide 1
Normalized name: furosemide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 1 mg/kg after ISDN
Study: 24245807
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioral therapy (ICBT) for 10 weeks
Study: 21148119
Drug: Topiramate 64
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 64 mg/day
Study: 18308157
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without distal protection (n = 314)
Study: 9526578
Drug: Fenretinide (4-HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide (4-HPR) at a dose of 200 mg per os every day for 5 years
Study: 8345067
Drug: Short protocol
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short protocol (buserelin 1 mg/day intranasally from cycle day 1 and HMG 2 ampoules/day from day 3 until HCG administration)
Study: 8345067
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (buserelin 1 mg/day intranasally from cycle day 1 for at least 14 days, then HMG 2 ampoules/day added)
Study: 29455894
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for MS-related fatigue, 16-week treatment.
Study: 27498916
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation (control)
Study: 23333044
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of L-arginine (500 mg, twice daily for two weeks)
Study: 8771664
Drug: Interferons (alpha‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferons (alpha‐2 and gamma‐interferons) administered in daily doses of 15,000‐25,000 IU/kg and 1500‐2500 IU/kg, respectively.
Study: 1614182
Drug: Inhaled amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amiloride (10(‐3)M), twice daily for two months
Study: 1614182
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline (control), twice daily for two months
Study: 3886209
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AVP infusion (75 pmol/min)
Study: 20233185
Drug: Lercanidipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (2 mg)
Study: 20233185
Drug: Amlodipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (1 mg)
Study: 16649829
Drug: Mirtazapine treatment
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine treatment
Study: 9000826
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (high and low doses)
Study: 16249073
Drug: Agomelatine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25 mg and 50 mg/day)
Study: 10733168
Drug: CHIRON CMV
Normalized name: opopanax chironium whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIRON CMV gB subunit vaccine combined with MF59 adjuvant
Study: 8737128
Drug: Amoxycillin 1
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1 g tid plus ofloxacin 200 mg bid
Study: 20937045
Drug: rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifaximin 1200 mg/day plus partially hydrolysed guar gum 5 g/day for 10 days
Study: 16326121
Drug: Salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week and a single dose of salmeterol/fluticasone immediately before allergen challenge (T3)
Study: 16326121
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment and a single dose of placebo immediately before allergen challenge (T1)
Study: 16326121
Drug: Salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone combination (50/250 mcg by Diskus) for 1 week
Study: 12952110
Drug: Omalizumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Study: 7497558
Drug: diltiazem 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 0.3 mg.kg‐1 (Group D, n = 12)
Study: 2023098
Drug: Ranitidine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 600 mg daily for 28 days
Study: 8707167
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg)
Study: 19640331
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d for 4 weeks)
Study: 17244765
Drug: Alprazolam, Olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, Olanzapine, Risperidone (test drugs)
Study: 14699269
Drug: Prolotherapy injections
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy injections (20% glucose/0.2% lignocaine)
Study: 7502546
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (11 g/day)
Study: 7502546
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (CO) supplementation (11 g/day)
Study: 2248531
Drug: Amoxycillin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (25 mg/kg/day) plus cimetidine for six weeks
Study: 23255270
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no joint infusion)
Study: 11069509
Drug: 5%, 10%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%, 10%, and 25% dilutions of FP cream under wet wrap
Study: 11069509
Drug: 0%, 5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0%, 5%, 10%, and 25% dilutions of FP cream applied on the whole body under wet wrap
Study: 6425893
Drug: Phospholipid liposomes
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid liposomes (PL) 250 mg IV bolus plus additional 250 mg infused IV over 60 minutes
Study: 29843492
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daily clopidogrel
Study: 27388980
Drug: Intraoperative sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative sufentanil (0.25 μg × kg−1 bolus, 0.15 μg × kg−1, repetition after 60 min)
Study: 23583011
Drug: Lurasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-160 mg/day)
Study: 23583011
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (200-800 mg/day)
Study: 17713342
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution
Study: 11052580
Drug: Tailored FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored FEC regimen with G-CSF support (n=251)
Study: 1739192
Drug: Generic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic albuterol MDI (2 puffs, 180 micrograms)
Study: 28609389
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Study: 28609389
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Study: 21292793
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide as a slow intravenous infusion over 15 min plus placebo (SIG)
Study: 21292793
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide as an intravenous bolus infusion over 2 min plus placebo (BIG)
Study: 8697059
Drug: Forskolin ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forskolin ointment, applied 5 times a week for 4 weeks, with diet and walking
Study: 8697059
Drug: Yohimbine ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine ointment, applied 5 times a week for 4 weeks, with diet and walking
Study: 8697059
Drug: Aminophylline ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline ointment, 10%, applied 5 times a week for 6 weeks, with diet and walking
Study: 26340658
Drug: Nebulised tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised tobramycin (300 mg twice daily for 3 months)
Study: 23879671
Drug: Azithromycin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1500 mg/week for four weeks)
Study: 15541405
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of levonorgestrel (LNG)
Study: 15541405
Drug: Single 0.75-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 0.75-mg dose of levonorgestrel (half dose)
Study: 2564505
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline ethylenediamine (aminophylline), 7 mg/kg
Study: 2564505
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of theophylline (375 mg)
Study: 2564505
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of theophylline ethylenediamine
Study: 31593088
Drug: Bronchial blockers
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial blockers (BB)
Study: 30716942
Drug: Synbiotic group
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic group (SG): 40 g of extruded sorghum plus 100 mL of unfermented probiotic milk
Study: 17419259
Drug: Placebo (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (continuous infusion for 48 hours)
Study: 15266769
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of meloxicam (Group M, n = 27)
Study: 11504270
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral [14C]omapatrilat
Study: 28159194
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg
Study: 29453687
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg
Study: 24725355
Drug: Condoms plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condoms plus emergency contraception pills (ECP) (Levonorgestrel)
Study: 24698485
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily
Study: 25944344
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily
Study: 12686241
Drug: Expensive combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expensive combination (sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) and BSS Plus)
Study: 9370845
Drug: Cisatracurium 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.20 mg.kg‐1
Study: 2885187
Drug: nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.2 mg/kg
Study: 2885187
Drug: morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.2 mg/kg
Study: 31062377
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of mother's milk (0.2 mL of mother's colostrum or milk prior to gavage feeding)
Study: 31062377
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of mother's milk
Study: 27488326
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (ST)
Study: 23107871
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 150 mg of vismodegib for 7 days
Study: 23107871
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg of moxifloxacin
Study: 8923359
Drug: sCT 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT 100 IU/day and calcium (Ca) 500 mg/day
Study: 3535473
Drug: Diltiazem therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem therapy for 14 days
Study: 15960558
Drug: Second-generation antidepressants
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antidepressants (primarily fluoxetine, duration 6 to 12 weeks)
Study: 15960558
Drug: First-generation antidepressants
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antidepressants (including placebo, phenelzine, and imipramine, N = 420)
Study: 10338172
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg morphine + 30 mg ketorolac (group KM)
Study: 10338172
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac (group K30)
Study: 10338172
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ketorolac (group K60)
Study: 1938398
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (phase-adapted therapy using diverse topical modalities)
Study: 6996897
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg intravenously)
Study: 26497535
Drug: Mindfulness-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Therapy (MBT)
Study: 30222962
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid treatment
Study: 30222962
Drug: Baseline triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline triglyceride level ≤ 154 mg/dL
Study: 30222962
Drug: Baseline aspartate
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline aspartate aminotransferase level ≤ 49 U/L
Study: 30222962
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in alanine aminotransferase level at week 24 by 17 U/L or more
Study: 22760341
Drug: 3-day combined
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day combined clavulanate/amoxicillin preparation
Study: 22760341
Drug: 10-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day amoxicillin treatment
Study: 15001195
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily) + diet
Study: 9695299
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms, twice a day for 3 weeks)
Study: 9695299
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 mg, twice a day for 3 weeks)
Study: 9695299
Drug: Salmeterol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (25 micrograms, twice a day for 3 weeks)
Study: 2809777
Drug: 100-g carbohydrate
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g carbohydrate meal
Study: 2809777
Drug: 50-g glucose
Normalized name: glucose 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-g glucose load (Glucola)
Study: 342621
Drug: Trivalent vaccine
Normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent vaccine (A/New Jersey/76, A/Victoria/75, B/Hong Kong/73)
Study: 25990482
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg misoprostol sublingually
Study: 12753338
Drug: Reinforced group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced group (n = 114) received IFN-2b 6 million units (MU) thrice weekly (TIW) and ribavirin for 48 weeks
Study: 9354208
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate b.d.
Study: 9354208
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide dinitrate b.d.
Study: 2873440
Drug: Inhaled platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled platelet activating factor (PAF)
Study: 31802559
Drug: Curcumin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1,500 mg/day)
Study: 20438830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-teratogenic agents)
Study: 15735614
Drug: BIBN4096BS (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN4096BS (2.5 mg)
Study: 1353996
Drug: Cetirizine (CTZ)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (CTZ) 10 mg once a day for 3 weeks
Study: 1353996
Drug: Terfenadine (TER)
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine (TER) 60 mg b.i.d. for 3 weeks
Study: 6407047
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate (0.1 mg)
Study: 6407047
Drug: Naloxone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.2 or 0.4 mg)
Study: 28957983
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy intervention (modified constraint-induced movement therapy) for 3 hours for 10 consecutive days
Study: 28957983
Drug: Individual modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual modified constraint-induced movement therapy for 3 hours for 10 consecutive days
Study: 20590736
Drug: Voglibose 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.2 mg thrice daily
Study: 24843649
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg once daily
Study: 16270633
Drug: Dexamethasone 1.0
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.0 mg/kg b.i.d on two days
Study: 10635302
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (UFT less than 300 mg/day, 5 days a week, and/or 5‐FU less than 440 mg/m2/24 hr once a week)
Study: 7772361
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg intravenous (i.v.) ondansetron
Study: 7772361
Drug: 0.075 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg i.v. droperidol
Study: 2373131
Drug: Metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR 50 mg
Study: 22673961
Drug: Monthly practice
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly practice of CPR skills
Study: 16952675
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alfuzosin daily
Study: 8178408
Drug: KLH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLH (1 mg intracutaneously, followed by 30 mg weekly for 6 weeks and then monthly for 1 year)
Study: 30466622
Drug: A. afra
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. afra tea infusion (1l/d of dry leaf/twig tea infusions divided into 3 aliquots daily for 7 days)
Study: 30466622
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) treatment (followed manufacturer posology)
Study: 30466622
Drug: PZQ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ and A. afra treatment in females
Study: 30466622
Drug: A. annua
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. annua treatment
Study: 12593999
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate monotherapy
Study: 10330960
Drug: Antilymphocyte antibody
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte antibody induction therapy
Study: 10330960
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with cyclosporine, azathioprine, and prednisone
Study: 2205078
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid treatment
Study: 25043197
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) 120 μg